ALK and non-small cell lung carcinoma: A number of somatic mutations, oncogenic rearrangements or copy number variations in NSCLC tumors have been identified, including EGFR exon 19 deletions, L858R or T790M mutations, MET exon 14 skipping mutations, ALK or ROS1 rearrangements, MET, EGFR or HER2 copy number increases2.